Discussion
The preliminary findings suggest that IPSRT-G delivered
adjunctive to medication in an intensive 2-week program is
feasible and may contribute to improved depressive symptoms
and maintenance of improvement at 12 weeks for
women with bipolar disorder. The trend toward improvement
in mania scores supports the overall-mood-stabilizing
benefit of IPSRT-G and the unlikelihood that depression
switching to mania is responsible for the outcome. Despite
improvement, only 33% met remission criteria at 2weeks and
16% met remission criteria at 12 weeks.